Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene

Science

Volumn 273, Issue 5279, 1996, Pages 1222-1225

  Yang, Na N ^a   Venugopalan, Murali ^a   Hardikar, Sushant ^a   Glasebrook, Andrew ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DNA; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; PURINE DERIVATIVE; RALOXIFENE; TRANSFORMING GROWTH FACTOR BETA3;

ARTICLE; BONE REMODELING; CONTROLLED STUDY; DNA BINDING; GENE ACTIVATION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

EID: 0029841146     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.273.5279.1222     Document Type: Article

References (34)

1. J. N. Anderson, in Biological Regulation and Development, R. F. Goldberger and K. R. Yamamoto, Eds. (Plenum, New York, 1984), vol. 3B, pp. 169-212; R. M. Evans, Science 240, 889 (1988).
2. J. N. Anderson, in Biological Regulation and Development, R. F. Goldberger and K. R. Yamamoto, Eds. (Plenum, New York, 1984), vol. 3B, pp. 169-212; R. M. Evans, Science 240, 889 (1988).
3. V. Kumar et al., Cell 51, 941 (1987); L. Klein-Hitpass, M. Schorpp, U. Wagner, G. U. Ryffel, ibid. 46, 1053 (1986).
4. V. Kumar et al., Cell 51, 941 (1987); L. Klein-Hitpass, M. Schorpp, U. Wagner, G. U. Ryffel, ibid. 46, 1053 (1986).
5. J. A. Lees, S. E. Fawell, M. G. Parker, J. Steroid Biochem. 34, 33 (1989); L. Tora et al., ibid. 59, 477 (1989).
6. J. A. Lees, S. E. Fawell, M. G. Parker, J. Steroid Biochem. 34, 33 (1989); L. Tora et al., ibid. 59, 477 (1989).
7. V. C. Jordan and C. S. Murphy, Endocrine Rev. 11, 578 (1990); A. E. Wakeling and J. Bowler, J. Steroid Biochem. 31, 645 (1988); C. D. Jones et al., J. Med. Chem. 27, 1057 (1984); W. L. Kraus and B. S. Katzenellenbogen, Endocrinology 132, 2371 (1993).
8. V. C. Jordan and C. S. Murphy, Endocrine Rev. 11, 578 (1990); A. E. Wakeling and J. Bowler, J. Steroid Biochem. 31, 645 (1988); C. D. Jones et al., J. Med. Chem. 27, 1057 (1984); W. L. Kraus and B. S. Katzenellenbogen, Endocrinology 132, 2371 (1993).
9. V. C. Jordan and C. S. Murphy, Endocrine Rev. 11, 578 (1990); A. E. Wakeling and J. Bowler, J. Steroid Biochem. 31, 645 (1988); C. D. Jones et al., J. Med. Chem. 27, 1057 (1984); W. L. Kraus and B. S. Katzenellenbogen, Endocrinology 132, 2371 (1993).
10. V. C. Jordan and C. S. Murphy, Endocrine Rev. 11, 578 (1990); A. E. Wakeling and J. Bowler, J. Steroid Biochem. 31, 645 (1988); C. D. Jones et al., J. Med. Chem. 27, 1057 (1984); W. L. Kraus and B. S. Katzenellenbogen, Endocrinology 132, 2371 (1993).
11. N. N. Yang et al., Endocrinology 137, 2075 (1996).
12. M. C. Horowitz, Science 260, 626 (1993); A. A. Nabulsi et al., N. Engl. J. Med. 328, 1069 (1993).
13. M. C. Horowitz, Science 260, 626 (1993); A. A. Nabulsi et al., N. Engl. J. Med. 328, 1069 (1993).
14. L. J. Black et al., J. Clin. Invest. 93, 63 (1994); M. W. Draper et al., J. Bone Miner. Res. 11, 835 (1996); R. R. Love et al., Ann. Intern. Med. 115, 860 (1991); R. R. Love et al., N. Engl. J. Med. 326, 852 (1992).
15. L. J. Black et al., J. Clin. Invest. 93, 63 (1994); M. W. Draper et al., J. Bone Miner. Res. 11, 835 (1996); R. R. Love et al., Ann. Intern. Med. 115, 860 (1991); R. R. Love et al., N. Engl. J. Med. 326, 852 (1992).
16. L. J. Black et al., J. Clin. Invest. 93, 63 (1994); M. W. Draper et al., J. Bone Miner. Res. 11, 835 (1996); R. R. Love et al., Ann. Intern. Med. 115, 860 (1991); R. R. Love et al., N. Engl. J. Med. 326, 852 (1992).
17. L. J. Black et al., J. Clin. Invest. 93, 63 (1994); M. W. Draper et al., J. Bone Miner. Res. 11, 835 (1996); R. R. Love et al., Ann. Intern. Med. 115, 860 (1991); R. R. Love et al., N. Engl. J. Med. 326, 852 (1992).
18. A. L. Glasebrook, D. L. Philips, N. N. Yang, unpublished data.
19. 378, although eight unrelated amino acids are added at the COOH-terminus. due to a cloning artifact. The predicted molecular size of the encoded protein (43 kD) was also confirmed by immunoblot analysis.
20. 378, although eight unrelated amino acids are added at the COOH-terminus. due to a cloning artifact. The predicted molecular size of the encoded protein (43 kD) was also confirmed by immunoblot analysis.
21. 378, although eight unrelated amino acids are added at the COOH-terminus. due to a cloning artifact. The predicted molecular size of the encoded protein (43 kD) was also confirmed by immunoblot analysis.
22. Total RNA from MG63 cells was prepared as described (4). A TGF-β3 cDNA probe (nt 200 to 5663) was generated by polymerase chain reaction amplification with the oligonucleotides 5′-TGTGCTGGGGTCTCTTCC-3′ and 5′-GTGAGGTTTGTTGCTTGT-3′ as primers. A human glyceraldehyde phosphate dehydrogenase gene probe (nt 471 to 740) (GenBank accession number M17851) was used as an internal control.
23. B. A. Arrick, R. L. Grendell, L. A. Griffin, Mol. Cell. Biol. 14, 619 (1994).
24. N. J. MacLusky, F. Naftolin, L. C. Krey, S. Franks, J. Steroid Biochem. 15, 111 (1981); J. Fishman, J. Endocrinol. 89, 59 (1981): S. Lieberman, ibid. 111, 519 (1986); T. Fotsis et al., Nature 368, 237 (1994).
25. N. J. MacLusky, F. Naftolin, L. C. Krey, S. Franks, J. Steroid Biochem. 15, 111 (1981); J. Fishman, J. Endocrinol. 89, 59 (1981): S. Lieberman, ibid. 111, 519 (1986); T. Fotsis et al., Nature 368, 237 (1994).
26. N. J. MacLusky, F. Naftolin, L. C. Krey, S. Franks, J. Steroid Biochem. 15, 111 (1981); J. Fishman, J. Endocrinol. 89, 59 (1981): S. Lieberman, ibid. 111, 519 (1986); T. Fotsis et al., Nature 368, 237 (1994).
27. N. J. MacLusky, F. Naftolin, L. C. Krey, S. Franks, J. Steroid Biochem. 15, 111 (1981); J. Fishman, J. Endocrinol. 89, 59 (1981): S. Lieberman, ibid. 111, 519 (1986); T. Fotsis et al., Nature 368, 237 (1994).
28. E. Nedivi, G. S. Basi, I. V. Akey, J. H. P. Skene, J. Neurosci. 12, 691 (1992); M. F. Young et al., J. Biol. Chem. 264, 450 (1989); S. J. Friezner Degen, J. L. Heckel, E. Reich, J. L. Degen, Biochemistry 26, 8270 (1987); V. V. Lobanenkov et al., Oncogene 5, 1743 (1990); E. H. Postel, S. J. Berberich, S. J. Flint, O.A. Ferrone, Science 261, 478 (1993).
29. E. Nedivi, G. S. Basi, I. V. Akey, J. H. P. Skene, J. Neurosci. 12, 691 (1992); M. F. Young et al., J. Biol. Chem. 264, 450 (1989); S. J. Friezner Degen, J. L. Heckel, E. Reich, J. L. Degen, Biochemistry 26, 8270 (1987); V. V. Lobanenkov et al., Oncogene 5, 1743 (1990); E. H. Postel, S. J. Berberich, S. J. Flint, O.A. Ferrone, Science 261, 478 (1993).
30. E. Nedivi, G. S. Basi, I. V. Akey, J. H. P. Skene, J. Neurosci. 12, 691 (1992); M. F. Young et al., J. Biol. Chem. 264, 450 (1989); S. J. Friezner Degen, J. L. Heckel, E. Reich, J. L. Degen, Biochemistry 26, 8270 (1987); V. V. Lobanenkov et al., Oncogene 5, 1743 (1990); E. H. Postel, S. J. Berberich, S. J. Flint, O.A. Ferrone, Science 261, 478 (1993).
31. E. Nedivi, G. S. Basi, I. V. Akey, J. H. P. Skene, J. Neurosci. 12, 691 (1992); M. F. Young et al., J. Biol. Chem. 264, 450 (1989); S. J. Friezner Degen, J. L. Heckel, E. Reich, J. L. Degen, Biochemistry 26, 8270 (1987); V. V. Lobanenkov et al., Oncogene 5, 1743 (1990); E. H. Postel, S. J. Berberich, S. J. Flint, O.A. Ferrone, Science 261, 478 (1993).
32. E. Nedivi, G. S. Basi, I. V. Akey, J. H. P. Skene, J. Neurosci. 12, 691 (1992); M. F. Young et al., J. Biol. Chem. 264, 450 (1989); S. J. Friezner Degen, J. L. Heckel, E. Reich, J. L. Degen, Biochemistry 26, 8270 (1987); V. V. Lobanenkov et al., Oncogene 5, 1743 (1990); E. H. Postel, S. J. Berberich, S. J. Flint, O.A. Ferrone, Science 261, 478 (1993).
33. 32P-labeled RRE probe (1 ng) was incubated in binding buffer [10 mM tris-HCl (pH 7.5), 50 mM NaCl, 1 mM EDTA, 5 mM DTT, and 2 μg of sonicated herring sperm DNA] for 30 min at room temperature. MG63 cells were lysed in 250 μl of lysis buffer [0.4 M KCl, 20% glycerol, 2 mM DTT, and 20 mM Hepes-NaOH (pH 7.8)], and the lysate was centrifuged at 80,000g for 1 hour at 2°C. DNA oligonucleotides were synthesized as the following complementary sequences: RRE probe, 5′-TCGAGGAGAGAGAGGGAGAGGAGCGAGAGGGAGAGGGAGAGGGAGAGA-3′ and 5′-AGCTTCTCTCCCTCTCCCTCTCCCTCTCGCTCCTCTCCCTCTCTCTCC-3′; ERE oligonucleotide, 5′-CTAGAAAGTCAGGTCACAGTGACCTG-3′ and 5′-TATGATCAGGTCACTGTGACCTGACT-3′; and CRE oligonucleotide, 5′-TCGAGCAAAATTGACGTCATGGTAATTAC-3′ and 5′-TCGAGTAATTACCATGACGTCAATTTTGC-3′. The AP-1 binding site oligonucleotide was obtained from Oncogene Science. Monoclonal antibodies (500 ng) to the ER DNA binding domain (clone ER33; Affinity BioReagents) or to the ER ligand binding domain (C11, 2D8.B4, and B5; Eli Lilly and Co.), or a nonspecific immunoglobulin G2a antibody (Eli Lilly and Co.), were included in antibody mobility-shift experiments.
34. We thank D. L. Phillips and L. Short for providing the ER antibodies and estrogen metabolite binding data; B. Katzenellenbogen for the ER constructs; G. L. Greene for the human progesterone receptor cDNA clone pHPR-65; and J. D. Termine, J. Hock, and A. H. Tashjian Jr. for discussions and comments on the manuscript.